Loading stock data…
ERAS
$10.03-0.62 (-5.82%)
Market ClosedLast close May 1
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Erasca, Inc. in the Healthcare sector is trading at $10.03. The stock is currently 59% below its 52-week high of $24.28, remaining 47.1% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why ERAS maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.03
Potential Upside
5%
Whystock Fair Value$10.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$20.70+106.4%
Range$9.00 – $30.00
Fundamentals
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.30%
Volume
Today's trading volume
9.57M
Recent News
Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 27, shares of Erasca dropped sharply after Revolution Medicines Inc. (NASDAQ:RVMD) accused the company of infringing patents and misusing trade secrets tied to its cancer drug candidate ERAS-0015. Revolution claims the therapy […]
Erasca (ERAS) Recoups 16.9% Gain on Cancer Treatment Optimism
Erasca Inc. (NASDAQ:ERAS) is one of the 10 Stocks Delivering Eye-Popping Gains. Erasca snapped a four-day losing streak on Thursday, soaring 16.90 percent to close at $10.65 apiece, as investors resorted to bargain-hunting following a steep plunge in the previous trading days, with sentiment fueled by renewed optimism for its cancer treatment candidate. It can […]
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results
Tango Therapeutics stock has soared this year on its pancreatic cancer treatment combination with Revolution Medicines.
Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges
Erasca reports patient death tied to severe side effects, while rival Revolution Medicines files patent claim and gains 10%.
Erasca stock sinks 50% after patient death in drug trial
A 66-year-old man developed severe lung inflammation about a month after starting ERAS-0015 and later died after withdrawing supportive care